Core Viewpoint - Gilead Sciences (GILD.US) has received approval from the European Commission for its HIV-1 capsid inhibitor Yeytuo (lenacapavir) as a pre-exposure prophylaxis (PrEP) therapy to reduce the risk of HIV-1 infection in high-risk adults and adolescents weighing at least 35 kilograms [1] Group 1 - Yeytuo is the first biannual HIV PrEP therapy approved in the EU [1] - The approval is based on the results of Phase 3 clinical trials, PURPOSE 1 and PURPOSE 2 [1] - Lenacapavir is a "first-in-class" long-acting HIV capsid inhibitor that interferes with the assembly and disassembly of the HIV capsid protein, acting at multiple stages of the viral life cycle [1]